Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of “Moderate Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been given an average rating of “Moderate Buy” by the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $191.57.

Several equities analysts have issued reports on ASND shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. TD Cowen cut their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, Oppenheimer cut their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at $30,000. Blue Trust Inc. grew its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 328 shares during the period. GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after buying an additional 214 shares during the last quarter. Signaturefd LLC raised its position in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 80 shares during the period. Finally, Pursue Wealth Partners LLC purchased a new position in Ascendis Pharma A/S in the third quarter valued at about $217,000.

Ascendis Pharma A/S Trading Up 2.6 %

ASND stock opened at $130.66 on Monday. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The stock has a 50-day moving average price of $133.63 and a 200-day moving average price of $132.85. The firm has a market cap of $7.93 billion, a PE ratio of -16.17 and a beta of 0.65.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.